Biomarker qualification via public-private partnerships

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 21-23

  Eck, S L ^a   Paul, S M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOHEXYL 1 (4 METHANESULFONYLPHENYL)CYCLOPROPANECARBOXYLIC ACID 2 THIAZOLYLAMIDE; ADIPONECTIN; BIOLOGICAL MARKER; EXENDIN 4; FIBROBLAST GROWTH FACTOR 21; FLUCLOXACILLIN; GK 50; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL PHARMACOLOGY; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG SAFETY; DRUG UTILIZATION; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADIPONECTIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72849113611     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.193     Document Type: Short Survey

References (4)

1. Wagner, J.A. et al. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin. Pharmacol. Ther. 86, 619-625 (2009).
2. Ashiya, M. & Smith, R.E.T. Non-insulin therapies for type 2 diabetes. Nat. Rev. Drug Disc. 6, 777-778 (2007).
3. Chen, W.W. et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116, 65-68 (2008).
4. Daly, A.K. et al. HLA-B&z.ast;5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819 (2009).